Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Ipsen SA (IPN)

Paris
Currency in EUR
108.90
-0.50(-0.46%)
Closed
IPN Scorecard
Full Analysis
Trading at a low P/E ratio relative to near-term earnings growth
Fair Value
Day's Range
107.50109.20
52 wk Range
99.70126.70
Key Statistics
Edit
Prev. Close
109.4
Open
109
Day's Range
107.5-109.2
52 wk Range
99.7-126.7
Volume
82.49K
Average Volume (3m)
60.64K
1-Year Change
6.63%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IPN Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
128.19
Upside
+17.71%
Members' Sentiments
Bearish
Bullish
ProTips
Valuation implies a strong free cash flow yield
Show more

Ipsen Company Profile

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Employees
5325
Market
France

Compare IPN to Peers and Sector

Metrics to compare
IPN
Peers
Sector
Relationship
P/E Ratio
13.5x20.5x−0.7x
PEG Ratio
0.270.130.00
Price/Book
2.2x2.9x2.6x
Price / LTM Sales
2.6x2.3x3.2x
Upside (Analyst Target)
9.7%20.8%44.5%
Fair Value Upside
Unlock14.7%6.6%Unlock

Analysts' Recommendations

6 Buy
10 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 128.19

(+17.71% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 8.23
Dividend Yield
1.10%
Industry Median 3.79%
Annualised payout
1.2000
Paid annually
5-Years Growth
+3.71%
Growth Streak

People Also Watch

74.80
LTEN
-0.86%
24.06
RXL
-1.55%
31.18
EDEN
-0.38%
82.80
FOUG
-3.04%
114.70
TRIA
-3.69%

FAQ

What Is the Ipsen (IPN) Stock Price Today?

The Ipsen stock price today is 108.90

What Stock Exchange Does Ipsen Trade On?

Ipsen is listed and trades on the Paris stock exchange.

What Is the Stock Symbol for Ipsen?

The stock symbol for Ipsen is "IPN."

Does Ipsen Pay Dividends? What’s The Current Dividend Yield?

The Ipsen dividend yield is 1.10%.

What Is the Ipsen Market Cap?

As of today, Ipsen market cap is 8.89B.

What is Ipsen Earnings Per Share?

The Ipsen EPS is 8.23.

What Is the Next Ipsen Earnings Date?

Ipsen will release its next earnings report on 13 Feb 2025.

From a Technical Analysis Perspective, Is IPN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.